Loading clinical trials...
Loading clinical trials...
A Prospective Phase II Clinical Study of Orelabrutinib in Combination With Lenalidomide and Rituximab (OLR) in First-line Treatment of Mantle Cell Lymphoma
Conditions
Interventions
Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
Locations
1
China
Tianjin Medical University Cancer Insititute & Hospital
Tianjin, Tianjin Municipality, China
Start Date
September 30, 2021
Primary Completion Date
October 15, 2022
Completion Date
October 15, 2023
Last Updated
November 11, 2021
NCT05529069
NCT06263491
NCT05006716
NCT06026319
NCT03523975
NCT01804686
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions